Recent events
Recent events tied to this brand in public sources.
Back to profile20 entries
2022
Glenmark licenses Ryaltris commercialization to Lotus in Southeast Asian markets
Glenmark Specialty S.A., a Swiss subsidiary of Glenmark Pharmaceuticals, entered into a licensing agreement with Lotus International for commercializing the Ryaltris nasal spray in Singapore, Hong Kong and Vietnam, subject to regulatory approvals. Glenmark will manufacture and supply the product, and Lotus will commercialize it.
2022
FDA approves Ryaltris nasal spray
The US Food and Drug Administration approved Ryaltris, a prescription nasal spray for seasonal allergic rhinitis, for adults and pediatric patients aged 12 and older. It is manufactured by Glenmark Specialty SA, a subsidiary of Glenmark Pharmaceuticals.
2021
Glenmark launches two diabetes drug brands in India
Glenmark Pharmaceuticals said it launched a fixed-dose combination drug for diabetes in India under the brand names Remo MV and Remozen MV. The combination contains remogliflozin, vildagliptin and metformin.
2021
Glenmark and SaNOtize announce strategic partnership for nasal spray
Glenmark Pharmaceuticals and SaNOtize Research & Development Corp. announced an exclusive long-term strategic partnership to manufacture, market and distribute the Nitric Oxide Nasal Spray for COVID-19 treatment in India and the named Asian markets.
2021
Glenmark launches Tiogiva in the UK
Glenmark Pharmaceuticals launched Tiogiva, a bioequivalent tiotropium bromide dry powder inhaler, in the UK for treatment of COPD.
2021
Glenmark signs Rohit Sharma as Candid Powder ambassador
Glenmark announced that Rohit Sharma had signed on to represent its Candid Powder brand as a brand ambassador.
2021
Glenmark receives India Pharma Innovation of the Year award
Glenmark Pharmaceuticals received the “India Pharma Innovation of the Year” Award as part of the India Pharma & India Medical Device Awards 2021.
2021
Glenmark launches SUTIB in India
Glenmark launched SUTIB, a generic version of Sunitinib oral capsules for treating kidney cancer, in India.
2020
Glenmark launches Remo V and Remozen V in India
Glenmark Pharmaceuticals launched fixed-dose Remogliflozin Etabonate and Vildagliptin products under the brand names Remo V and Remozen V in India for the management of Type 2 diabetes.
2020
Dr. Reddy's agrees to acquire selected Glenmark brands
Dr. Reddy's Laboratories announced a definitive agreement to acquire selected anti-allergy brands and associated intellectual property rights from Glenmark Pharmaceuticals for specified territories, subject to precedent actions and closing activities.
2020
Glenmark launches Nindanib in India
Glenmark Pharmaceuticals launched Nindanib, a generic branded version of nintedanib, in India to treat pulmonary fibrosis. The company claimed the medicine costs 5% of the innovator brand's cost in India.
2020
Glenmark appoints Dipankar Bhattacharjee to its board
Glenmark Pharmaceuticals announced Dipankar Bhattacharjee’s appointment as an Independent Non-Executive Director on its board for five years, effective August 14, 2020.
2020
Glenmark announces 400 mg FabiFlu version
Glenmark announced that it will introduce a 400 mg version of FabiFlu, an oral antiviral for treatment of mild to moderate COVID-19 in India. The company said the higher strength is intended to reduce the number of tablets patients need per day.
2020
Glenmark cuts FabiFlu price to Rs 75 per tablet
Glenmark Pharmaceuticals reduced the price of FabiFlu from Rs 103 to Rs 75 per tablet in India, citing gains from higher yields and better scale.
2020
Glenmark cuts FabiFlu price to Rs 75 per tablet
Glenmark Pharmaceuticals said on Monday that it cut the price of FabiFlu, its antiviral drug for mild to moderate COVID-19, by 27% to Rs 75 per tablet.
2020
Glenmark commences FabiFlu surveillance study
Glenmark said it had commenced a post-marketing surveillance study of FabiFlu to monitor the drug's efficacy and safety in 1,000 patients. The report does not describe a specific safety problem.
2020
Glenmark receives approval for FabiFlu
Glenmark Pharmaceuticals received manufacturing and marketing approval from India's Drugs Controller General for FabiFlu.
2020
India approves FabiFlu manufacturing and marketing
India's Drugs Controller General granted Glenmark Pharmaceuticals manufacturing and marketing approval for FabiFlu on Friday, according to the reports.
2019
Glenmark Baddi unit receives cGMP certificate
Glenmark Pharmaceuticals said the Czech regulator SUKL issued a certificate stating that its Baddi manufacturing facility complies with Good Manufacturing Practice requirements.
2019
Glenmark recalls Estradiol Vaginal inserts in the United States
Glenmark Pharmaceuticals is recalling about 217,000 cartons of Estradiol Vaginal inserts in the United States because of a defective delivery system, including complaints that the applicator plunger was difficult to push. The FDA report describes it as a voluntary Class II recall.